Skip to main content
NVO
NYSE Life Sciences

Novo Nordisk Initiates DKK 3.8 Billion Share Repurchase Program for 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$43.51
Mkt Cap
$213.267B
52W Low
$43.08
52W High
$93.8
52W Position info
1.0% above low
Off High info
54% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

NVO is trading near its 52-week low of $43.08 (1.0% above the low) on elevated volume (2.0× avg).

Summary

Novo Nordisk announced the initiation of a DKK 3.8 billion share repurchase program, part of a larger DKK 15 billion program for 2026, aimed at reducing share capital and fulfilling incentive obligations.


Key Events · Financing and Capital Events · NVO

  • Share Repurchase Program Initiated

    Novo Nordisk initiated a new share repurchase program for up to DKK 3.8 billion (approximately $551 million USD).

  • Part of Larger 2026 Program

    This program is a component of the company's overall DKK 15 billion (approximately $2.175 billion USD) share repurchase program for 2026.

  • Program Duration

    The current tranche will be executed during the trading period from February 4, 2026, through May 4, 2026.

  • Strategic Purpose

    The repurchase aims to reduce the company's share capital and meet obligations arising from share-based incentive programs.


Analysis · NVO · Life Sciences

Novo Nordisk's initiation of a DKK 3.8 billion share repurchase program, part of a larger DKK 15 billion allocation for 2026, signals management's confidence in the company's valuation. This move is particularly notable as the stock is trading near its 52-week low, suggesting a strategic effort to return value to shareholders and potentially support the stock price. The program aims to reduce share capital and fulfill obligations from share-based incentive programs, providing a positive signal amidst recent financial outlooks projecting a decline in sales and profit for 2026.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NVO was trading at $43.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $213.3B. The 52-week trading range was $43.08 to $93.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NVO - Latest Insights

NVO
Nov 04, 2026, 8:35 AM EST
Source: Benzinga
Importance Score:
8
Price at Filing: $42.91
Real-time Price: $40.56 info
Change: -$2.34 (-5%) info
Market Cap: $181.15B info
NVO
Nov 04, 2026, 7:47 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $42.90
Real-time Price: $40.56 info
Change: -$2.34 (-5%) info
Market Cap: $181.15B info
NVO
Nov 04, 2026, 4:00 AM EST
Source: Seeking Alpha
Importance Score:
9
Price at Filing: $41.96
Real-time Price: $40.56 info
Change: -$1.40 (-3%) info
Market Cap: $181.15B info
NVO
Oct 27, 2026, 3:10 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $39.16
Real-time Price: $40.56 info
Change: +$1.40 (+4%) info
Market Cap: $181.15B info
NVO
Oct 02, 2026, 5:53 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $36.88
Real-time Price: $40.56 info
Change: +$3.68 (+10%) info
Market Cap: $181.15B info